23andMe_Logo_grey.png
23andMe Reports FY2022 Third Quarter Financial Results
February 10, 2022 16:04 ET | 23andMe Holding Co.
Third quarter revenue of $57 million Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials Vision of genetics-based primary care offers potential for millions of...
23andMe_Logo_grey.png
23andMe to Report FY2022 Third Quarter Financial Results
January 27, 2022 16:05 ET | 23andMe Holding Co.
SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...
23andMe_Logo_grey.png
23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program
January 18, 2022 06:55 ET | 23andMe Holding Co.
GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database 23andMe...
23andMe_Logo_grey.png
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker
January 10, 2022 08:00 ET | 23andMe Holding Co.
SUNNYVALE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today received FDA clearance for a genetic health...
23andMe_Logo_grey.png
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
January 06, 2022 09:00 ET | 23andMe Holding Co.
23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey...
23andMe_Logo_grey.png
23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants
December 28, 2021 16:05 ET | 23andMe Holding Co.
SUNNYVALE, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the results of the completed...
23andMe_Logo_grey.png
23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer
November 30, 2021 09:15 ET | 23andMe Holding Co.
SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R....
23andMe_Logo_grey.png
23andMe Announces Redemption of All Outstanding Warrants
November 22, 2021 16:15 ET | 23andMe Holding Co.
SUNNYVALE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its...
23andMe_Logo_grey.png
23andMe Reports FY2022 Second Quarter Financial Results
November 10, 2021 16:05 ET | 23andMe Holding Co.
Second quarter revenue of $55 millionRecent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives SUNNYVALE,...
23andMe_Logo_grey.png
23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for Shareholders
November 03, 2021 16:30 ET | 23andMe, Inc.
SUNNYVALE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...